•   
  •   

Health & Fitness Merck says its Covid pill should be effective against Omicron

00:41  01 december  2021
00:41  01 december  2021 Source:   dailymail.co.uk

New Covid-19 pill in Germany exceeds all expectations as it reduces Coronavirus deaths by half

  New Covid-19 pill in Germany exceeds all expectations as it reduces Coronavirus deaths by half A new experimental Covid-19 pill reduced stays in hospital and deaths by half, according to German multinational science and technology The post New Covid-19 pill in Germany exceeds all expectations as it reduces Coronavirus deaths by half appeared first on CityAM.

MailOnline logo © Provided by Daily Mail MailOnline logo

Merck & Co believes its promising new Covid treatment is effective against the Omicron variant.

Molnupiravir, developed by the Kenilworth, New Jersey-based pharmaceutical, stops the virus from making copies of itself, which prevents it from spreading throughout the body.

Merck believes that since the drug does not target the spike protein, where many of the concerning Omicron variant mutations are occurring, its drug should be effective still.

Recent trial data has found the drug can reduce risk of death from the virus by 30 percent - but some vaccine and drug manufacturers fear their products will not be as effective against the recently discovered, highly mutated, strain.

Atea says experimental COVID-19 antiviral pill failed clinical trials

  Atea says experimental COVID-19 antiviral pill failed clinical trials A pill developed by Atea Pharmaceuticals Inc was not more effective than a placebo at reducing viral loads in mild-to-moderately ill COVID-19 patients in Phase II clinical trials.The company announced on Tuesday that the drug did not reduce Covid viral loads in patients compared to a placebo in the mid-stage study.

It comes as an advisory panel from the U.S. Food and Drug Administration (FDA) meets on Tuesday to decide whether or not Merck's therapy can receive emergency use authorization.

( © Provided by Daily Mail (

During a presentation to the FDA panel Tuesday, Daria Hazuda, vice president of Merck's infectious diseases and vaccines division said she believes the drug should have similar effectiveness against all new variants of the virus.

She also said that molnupiravir showed effectiveness against the Delta variant - which is still the dominant strain worldwide - in clinical trials.

But many other drug manufacturers are fearful that their products are less effective against the mutant virus strain.

Moderna CEO Stephane Bancel said on Monday that his company's COVID-19 vaccine may not provide as many antibodies to combat Omicron as it does for other strains.

Merck ready to deliver 10 million doses of its Covid pill by years end

  Merck ready to deliver 10 million doses of its Covid pill by years end Robert Davis, CEO of Merck, told CNBC on Thursday that his company is prepared to ship tens of millions of doses of the antiviral pill molnupiravir, pending regulatory approval.Robert Davis, CEO of the Kenilworth, New Jersey-based company, told CNBC on Thursday that the firm is ready to deploy massive shipments of the drug as soon as it gets the greenlight from the U.S. Food and Drug Administration (FDA).

BioNTech, who partnered with Pfizer for distribution of its vaccine, and Johnson & Johnson are both working on Omicron specific vaccines in the wake of fears their vaccines are now less effective.

Pfizer is also seeking approval for an antiviral Covid pill, though has not revealed any information on whether the company believes its drug is effective against the new strain.

195829957 © Provided by Daily Mail 195829957   Merck says its Covid pill should be effective against Omicron © Provided by Daily Mail

Regeneron, producer of an authorized monoclonal antibody Covid treatment, also believes its drug could be less effective against the variant.


Video: FDA: Merck COVID pill effective; experts will review safety (Yahoo! News)

The fears spawn from the high number of mutations the Omicron variant has compared to other virus strains.

Omicron, discovered last week by South African health officials, is found to have more than 50 mutations, with more than 30 being on the spike protein, the part of the virus that the vaccines target.

Covid fightback: UK to deploy 'groundbreaking' wonder-pill that cuts deaths by 30%

  Covid fightback: UK to deploy 'groundbreaking' wonder-pill that cuts deaths by 30% THE UK is further arming itself in the fightback against COVID-19 as a "groundbreaking" wonder-pill will be deployed to 10,000 Britons.Around 10,000 people are expected to take the drug.

Merck is confident that these mutations will not affect the way that its drug fights the virus.

Molnupiravir works by blocking the virus from replicating in the body.

It does so by introducing errors into Covid's genetic code, hampering its ability to multiply in human cells.

The medicine targets an enzyme that the virus relies on to generate copies of itself. Merck said this process should make the tablet equally effective at tackling new variants.

Two specific proteins are targeted by the drug, and each only have one mutation on them

Neither mutation is believed to be able to prevent the drug from being effective at preventing replication of the virus.

The drug has been deemed a 'game changer' by some due to its effectiveness in preventing hospitalization or death from the virus.

195829973 © Provided by Daily Mail 195829973   Merck says its Covid pill should be effective against Omicron © Provided by Daily Mail

Clinical trials find that it can reduce the risk of negative outcomes from the virus by between 30 to 50 percent.

It is also easier to administer than many other popular Covid treatments, as a patient only has to take pills, compared to the resource and equipment intensive process of delivering  monoclonal antibody treatments.

The drug is administered to Covid patients in four pill doses, twice a day for five days upon a person feeling symptoms of the virus.

Merck is seeking regulatory approval worldwide for the use of its drug, and has partnered with generic drug manufacturers to make it available in the developing world.

It has so far received approval in the UK, and EU regulators have allowed for it to be adminsitered in the most high risk patients, pending full approval.

Read more

Britain banking on COVID antivirals to get through Omicron winter .
Britain banking on COVID antivirals to get through Omicron winter(Reuters) - Britain expects to have antiviral COVID-19 pills produced by Merck & Co Inc and Pfizer available over the winter, its Antiviral Taskforce Chair said on Thursday, as Omicron continues its lightning advance through the country.

usr: 1
This is interesting!